Sagimet Biosciences (SGMT) Common Equity (2023 - 2024)
Sagimet Biosciences has reported Common Equity over the past 2 years, most recently at $170.7 million for Q3 2024.
- Quarterly results put Common Equity at $170.7 million for Q3 2024, up 74.39% from a year ago — trailing twelve months through Sep 2024 was $170.7 million (up 74.39% YoY), and the annual figure for FY2023 was $91.1 million, changed.
- Common Equity for Q3 2024 was $170.7 million at Sagimet Biosciences, down from $183.3 million in the prior quarter.
- Over the last five years, Common Equity for SGMT hit a ceiling of $190.0 million in Q1 2024 and a floor of -$198.4 million in Q2 2023.